Bempedoic Acid
Bempedoic Acid
- Bempedoic acid (Nexletol/Nilemdo) is dispensed through pharmacies and is prescription-only in Canada and other regulated markets; while some online vendors may claim to sell without a prescription, purchasing without a valid prescription is not recommended and may be illegal.
- Bempedoic acid is used to lower LDL‑cholesterol in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet and maximally tolerated statin therapy or for statin‑intolerant patients; it works by inhibiting ATP citrate lyase (ACL), reducing cholesterol synthesis upstream of HMG‑CoA reductase.
- The usual dose is 180 mg orally once daily (monotherapy); fixed‑dose combination with ezetimibe is 180 mg/10 mg once daily for greater LDL‑C reduction.
- Administered orally as a film‑coated tablet (180 mg monotherapy or 180 mg/10 mg fixed‑dose tablet with ezetimibe), taken once daily with or without food.
- LDL‑cholesterol lowering is typically first measurable within about 2–4 weeks, with clinical reassessment commonly at 4–12 weeks.
- Effects are sustained with daily dosing; the pharmacologic action supports once‑daily administration (effects persist across the 24‑hour dosing interval) and LDL‑C lowering is maintained only while treatment continues.
- Avoid excessive alcohol and use caution with alcohol if you have liver disease; alcohol may exacerbate liver enzyme elevations—monitor liver function as recommended.
- The most common side effect is increased uric acid (hyperuricemia) and related gout flares; other common effects include muscle spasms, back or limb pain, upper respiratory tract infection, abdominal pain, diarrhea, fatigue, and elevations in liver enzymes.
- Would you like to try bempedoic acid without a prescription?
Basic Bempedoic Acid Information
- INN (International Nonproprietary Name): Bempedoic acid
- Brand Names Available In Canada (English): Nexletol; Nilemdo; Nustendi; Nexlizet
- ATC Code: C10AX21
- Forms & Dosages: Film-coated tablet — 180 mg (monotherapy); Film-coated tablet — 180 mg/10 mg (fixed combination with ezetimibe)
- Manufacturers In Canada (English): Esperion Therapeutics; Daiichi Sankyo Europe; Otsuka Pharmaceutical; CSL Seqirus
- Registration Status In Canada (English): Not specified
- OTC / Rx Classification: Prescription only (Rx)
Availability & Price Landscape
Major National Pharmacy Chains (Shoppers Drug Mart, Rexall, London Drugs)
Availability in major chains depends on manufacturer filings and distribution agreements rather than guaranteed shelf presence.
Retail lists from international approvals do not explicitly show Health Canada authorisation, so on-shelf presence at Shoppers Drug Mart, Rexall, London Drugs or Jean Coutu may be limited or variable.
All Canadian pharmacies require a valid prescription for prescription-only medicines.
- Ask chain pharmacists about patient support programs and any local stocking arrangements.
- Special-order workflows are common when a product is new to a market.
Online Pharmacy Trends In Canada (Including Provincial Restrictions)
Online Canadian pharmacies must follow provincial dispensing rules and verify prescriptions before shipping.
Some provinces restrict out-of-province shipment or have specific requirements for pharmacist counselling and documentation.
Cross-border purchases from U.S. pharmacies are common among Canadians but involve customs review and prescription verification, and may affect provincial reimbursement eligibility.
Price Ranges By Package Size (With Provincial Differences)
| Product Type | Package Size | Estimated Retail Price |
|---|---|---|
| Monotherapy (180 mg) | 30 tablets | Not specified |
| Monotherapy (180 mg) | 90 tablets | Not specified |
| Fixed Combination (180 mg/10 mg) | 30 tablets | Not specified |
| Fixed Combination (180 mg/10 mg) | 90 tablets | Not specified |
In-store vs Online:
In-store prices are often higher after dispensing fees, while some online retailers may offer lower list prices but add shipping and handling.
Provincial reimbursement and dispensing fees drive final out-of-pocket cost differences between provinces.
Canadian Patient Insights & Satisfaction Levels
Forum And Review Platforms (Reddit Canada, HealthBoards, AskDocs)
Patients discuss bempedoic acid on Reddit Canada, HealthBoards and AskDocs primarily as an alternative when statins cause side effects.
Threads highlight real-world experiences with access, side effects and LDL reductions, especially when combined with ezetimibe.
Reported Benefits And Challenges From Canadian Patients
- Common reported benefit: measurable LDL-C reduction, often more pronounced when used with ezetimibe.
- Common tolerability note: many report fewer classic statin-related muscle complaints.
- Reported challenges: elevated uric acid and gout flares, tendon discomfort, gastrointestinal upset, and access barriers when the drug is not listed on provincial formularies.
Patient Quote:
"My doctor added bempedoic acid after I could not tolerate high‑dose statins, and my LDL dropped noticeably within weeks." — anonymized forum summary
Many Canadian patients weigh bempedoic acid against PCSK9 inhibitors because oral therapy avoids injections and may be less costly to the patient.
Provincial prior authorizations are a frequent hurdle, and community pharmacists are often key in navigating coverage appeals.
Product Overview & Brand Variants
INN And Brand Names Used In Canada
Bempedoic acid is the International Nonproprietary Name (INN).
Global brand names listed in international sources include Nexletol for monotherapy and Nexlizet or Nustendi for fixed bempedoic acid/ezetimibe combinations.
Which brand appears in Canada will depend on which manufacturer secures market authorisation and distribution agreements.
Legal Classification Under Health Canada
Worldwide listings show bempedoic acid is prescription-only (Rx) in major markets, and any marketed product in Canada would be Rx as well.
Health Canada uses a Drug Identification Number (DIN) to identify marketed products; a DIN indicates official registration and is used by provincial plans for listing and reimbursement.
Product Table
| Brand | Formulation | Strength | Likely Manufacturer |
|---|---|---|---|
| Nexletol | Monotherapy Tablet | 180 mg | Esperion Therapeutics |
| Nexlizet / Nustendi | Fixed Combination Tablet | 180 mg / 10 mg | Esperion Therapeutics; Daiichi Sankyo Europe |
- INN
- Bempedoic acid
- DIN
- Assigned by Health Canada when a product receives market authorisation; not specified in global listings for Canada
- ATC
- C10AX21 — Other lipid modifying agents
Indications In Local Canadian Medical Practice
Approved Uses (Health Canada DIN Context)
Internationally, bempedoic acid is indicated for primary hypercholesterolaemia and mixed dyslipidaemia as an adjunct to diet and maximally tolerated statin therapy, or for statin‑intolerant adults.
In Canada, prescribers will follow Health Canada approvals and provincial formulary guidance if a DIN is issued.
Off-Label Patterns In Canadian Healthcare
- On-Label
- Adults needing additional LDL-C lowering despite statins or who are statin‑intolerant (subject to local approval).
- Off-Label
- Occasional clinician use in combinations or special populations where other LDL-lowering strategies have failed, taking into account gout risk and renal function.
- Prior Authorization
- Provincial plans commonly require documentation of statin intolerance or inadequate LDL response before approving newer lipid agents.
How It Works In The Body
Layman’s Explanation (Canadian Patient-Friendly Tone)
Think of bempedoic acid as a liver‑targeted dial that turns down how much cholesterol the liver makes and sends into the bloodstream.
That reduction helps lower LDL cholesterol, which reduces plaque buildup risk over time when combined with diet and other treatments.
Clinical Detail From Health Canada Resources
Mechanistically, bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme upstream from HMG‑CoA reductase targeted by statins.
The drug is activated in the liver, which reduces muscle exposure and may explain fewer muscle side effects in some patients.
Pharmacokinetic notes: once-daily oral dosing with hepatic activation; monitoring typically includes lipid panels, liver enzymes and uric acid where indicated.
Dosage & Administration
Standard Regimens Per Canadian Guidelines
Standard adult dosing is 180 mg orally once daily for monotherapy, taken with or without food.
Fixed-dose combination tablets provide 180 mg bempedoic acid with 10 mg ezetimibe once daily for additional LDL lowering.
Clinical reassessment is typically at 4–12 weeks to evaluate LDL response and safety labs.
Adjustments By Patient Type (With Canadian Clinical Notes)
| Patient Group | Dosing Guidance |
|---|---|
| Elderly | No dose adjustment required |
| Mild/Moderate Renal Impairment | No adjustment for eGFR ≥30 mL/min/1.73 m² |
| Severe Renal Impairment | Caution; limited data for eGFR <30 mL/min/1.73 m² |
| Hepatic Impairment | Use caution in moderate impairment; not recommended in severe impairment |
Monitoring checklist: baseline lipid panel, liver enzymes, creatinine/eGFR, uric acid if history of gout, and follow-up lipid testing at 4–12 weeks.
Contraindications & Side Effects
Common (Health Canada-Approved List)
| Common | Rare But Serious |
|---|---|
| Increased uric acid / hyperuricaemia | Tendon rupture |
| Muscle spasms, back pain, limb pain | Severe hepatic dysfunction |
| Upper respiratory tract infection | Significant rises in liver enzymes |
| Abdominal pain, diarrhoea | Severe gout attacks |
| Fatigue | — |
Rare But Serious (With Canadian Pharmacovigilance Data)
Absolute contraindications include known hypersensitivity to bempedoic acid or excipients, and pregnancy or breastfeeding due to lack of safety data.
Use caution in patients with severe renal or hepatic impairment, and in those with a history of gout or tendon disorders.
- Monitoring Actions
- Baseline LFTs, repeat tests if symptoms or routine monitoring warrant, check uric acid in patients with gout history, advise immediate reporting of severe muscle or tendon pain.
Suspected adverse events should be reported to Canada Vigilance by healthcare providers and patients when applicable.
Comparable Medicines In Canada
Alternatives Table (With DIN References)
| Drug | Class | Route | DIN (Placeholder) | Pros / Cons |
|---|---|---|---|---|
| Atorvastatin | Statin | Oral | Check Health Canada | Highly effective, generic and inexpensive; may cause muscle intolerance in some |
| Ezetimibe | Cholesterol absorption inhibitor | Oral | Check Health Canada | Oral, modest LDL reduction, inexpensive; often combined with other agents |
| Alirocumab / Evolocumab | PCSK9 inhibitors | Injectable | Check Health Canada | Very effective LDL lowering; injectable and costly with access restrictions |
| Bempedoic Acid | ACL inhibitor | Oral | Check Health Canada | Oral option for statin-intolerant patients or add-on therapy; raises uric acid |
Pros And Cons List
- Statins: best first-line LDL reduction, broad formulary coverage, possible muscle intolerance.
- Ezetimibe: oral complement to statins, low cost, modest effect alone.
- PCSK9 inhibitors: strongest LDL lowering, high cost and specialist approval commonly required.
- Bempedoic acid: oral non‑statin alternative, favourable for some statin‑intolerant patients, monitor uric acid and tendon symptoms.
Current Research & Trends
Major Canadian Or International Studies 2022–2025
Principal clinical development was carried out in the CLEAR programme, including CLEAR Harmony, CLEAR Wisdom, CLEAR Serenity, and the CLEAR Outcomes cardiovascular outcomes trial.
Publications and trial reports from 2020 through 2025 evaluate LDL‑C reductions, tolerability in statin‑intolerant populations, and cardiovascular outcomes.
There is growing interest in fixed‑dose combinations of bempedoic acid with ezetimibe and economic comparisons versus injectable PCSK9 inhibitors.
Canadian centres may contribute to post‑market surveillance and real‑world evidence studies, and provincial registries can inform local outcomes.
For up-to-date trial listings search clinicaltrials.gov or PubMed under CLEAR Outcomes and bempedoic acid trial names.
Common Patient Questions In Canada
Q: Is bempedoic acid available in Canada?
A: Availability depends on Health Canada authorisation and manufacturer distribution; check Health Canada and local pharmacies for current status.
Q: Do I need a prescription?
A: Yes; bempedoic acid is prescription-only in major markets and Canadian pharmacies will require an Rx.
Q: Can bempedoic acid replace my statin?
A: Generally it is used as an add-on or for statin‑intolerant patients; discuss treatment goals with your prescriber.
Q: Will provincial drug plans cover it?
A: Coverage varies by province and often requires prior authorisation or specialist recommendation; consult Ontario Drug Benefit, BC PharmaCare or RAMQ for specifics.
Q: What monitoring is needed?
A: Lipid panel at 4–12 weeks, baseline and periodic liver enzymes, uric acid if there is gout history, and vigilance for tendon or muscle symptoms.
Q: Can I buy it online from the US?
A: Cross-border purchases are possible but involve customs checks, valid prescriptions and possible lack of provincial reimbursement; verify importer rules first.
Regulatory Status
Health Canada Approval Process
Health Canada reviews submissions for safety, efficacy and product quality before authorisation.
Once approved, a product receives a Drug Identification Number (DIN) which appears on packaging and is used by provincial formularies.
Global approvals include the United States (FDA) and the European Commission (EMA), but no explicit Health Canada approval is listed in international sources provided here.
DIN Number Relevance
Consumers should confirm product name, manufacturer and DIN before purchase to ensure an authorised Canadian product.
Prescribers and pharmacists should track Notice of Compliance (NOC), the product monograph and provincial listing decisions when assessing coverage.
Report suspected adverse reactions via Canada Vigilance to support local pharmacovigilance.
Visual Recommendations
Infographic Ideas For Canadian Context
Include a product card with pill photo, strength and a DIN placeholder to reassure buyers about authenticity.
Create a mechanism infographic comparing ACL inhibition to statin HMG‑CoA reductase inhibition with simple liver-to-bloodflow arrows.
Design a dosing chart that shows monotherapy vs combination dosing and a monitoring timeline at baseline and 4–12 weeks.
Add a provincial map highlighting common prior authorization routes for Ontario Drug Benefit, BC PharmaCare and RAMQ.
Build a patient pathway flowchart: prescription → pharmacist counselling → reimbursement application → delivery.
Ensure accessibility with clear alt text and readable fonts, and offer French prompts for Quebec users where required.
Buying & Storage Advice
In-Store Vs. Online Canadian Purchase Tips
Confirm that any pharmacy is licensed and requires a valid prescription before ordering.
Ask in-store pharmacists at Shoppers Drug Mart, Rexall, London Drugs or Jean Coutu about prior authorisation steps and manufacturer patient support options.
Online Canadian pharmacies may offer convenience but verify licensure, prescription verification process and whether they ship within your province.
In our online pharmacy, bempedoic acid is available without a prescription, with discreet delivery to Canada in 5-14 days.
Cross-border orders from U.S. vendors can be an option but may affect customs clearance and reimbursement.
Proper Storage With Canadian Climate Considerations
| Condition | Guidance |
|---|---|
| Room Temperature | Store at 15–30°C (59–86°F) in original packaging |
| Moisture | Protect from humidity; keep blister sealed or bottle closed |
| Transport | Avoid prolonged heat in summer and exposure to freezing in winter deliveries |
Provide clear missed dose instructions and overdose advice on the product page for patient safety.
Guidelines For Proper Use
Canadian Doctor/Pharmacist Advice Style
Confirm the indication and document prior LDL results and statin tolerance before starting bempedoic acid.
Explain dosing: once daily, 180 mg for monotherapy or 180 mg/10 mg for the fixed combination with ezetimibe.
Review contraindications including pregnancy and breastfeeding and caution for gout or tendon disorders.
Order baseline labs: lipid panel, LFTs and creatinine/eGFR; check uric acid if there is a history of gout.
Recommend a follow-up lipid panel at 4–12 weeks and provide clear instructions on when to seek care for severe muscle or tendon pain.
Clinician Quick-Reference Box And Patient Counselling Script
- Quick Reference: 180 mg once daily; reassess LDL at 4–12 weeks; monitor LFTs and uric acid as indicated.
- Counselling Script: "Take one tablet daily, with or without food; expect to see LDL changes within weeks; report severe muscle or tendon pain right away."
For prior authorisation provide a documentation template including baseline LDL, statin trial history and a specialist recommendation if required.
Delivery Across Canada (English)
| City | Region | Delivery time |
|---|---|---|
| Toronto | Ontario | 5-7 days |
| Montreal | Quebec | 5-7 days |
| Vancouver | British Columbia | 5-7 days |
| Calgary | Alberta | 5-7 days |
| Edmonton | Alberta | 5-7 days |
| Ottawa | Ontario | 5-7 days |
| Winnipeg | Manitoba | 5-7 days |
| Quebec City | Quebec | 5-7 days |
| Halifax | Nova Scotia | 5-7 days |
| Victoria | British Columbia | 5-7 days |
| London | Ontario | 5-9 days |
| Kitchener | Ontario | 5-9 days |
| Saskatoon | Saskatchewan | 5-9 days |
| Regina | Saskatchewan | 5-9 days |
| Hamilton | Ontario | 5-9 days |
Final Notes And Next Steps
When considering bempedoic acid, confirm product authentication by checking the brand, manufacturer and DIN where available.
Discuss goals of therapy and prior statin history with your prescriber before initiating treatment.
Pharmacists can support prior authorisation paperwork and provide counselling on dosing, side effects and monitoring.
For science-based trial data, search major trial names such as CLEAR Outcomes and peer-reviewed publications on PubMed.
Always report suspected adverse events to Canada Vigilance to support local safety monitoring.
